Wearable Cardiac Monitors Track Atrial Fibrillation

Cardiac Insight, Inc. announces that its FDA-approved Cardea SOLO™ ECG monitoring system is available for diagnosing atrial fibrillation following cardiac ablation. The company’s cardiac monitoring device supports a recent formal consensus statement by experts from 11 leading international cardiology organizations that recognizes the use of wearable sensing devices in patients who have undergone atrial fibrillation (AFib) ablation procedures.

 

The formal acknowledgement of wearable sensors was one of a series of recommendations for treating the millions of patients who have atrial fibrillation, a common rhythm disorder that increases the risk of heart failure and stroke. The expert consensus statement was collectively developed by the Heart Rhythm Society, European Heart Rhythm Association, European Cardiac Arrhythmia Society, among several others.

Free Newsletter

Like this article? Subscribe to FierceSensors!

The sensors industry is constantly changing as innovation runs the market’s trends. FierceSensors subscribers rely on our suite of newsletters as their must-read source for the latest news, developments and analysis impacting their world. Register today to get sensors news and updates delivered right to your inbox.

 

Cardiac ablation is an invasive procedure that is used to eliminate atrial fibrillation. Among its many applications, Cardea SOLO is a new, distinctive, cost-effective and timely solution for monitoring the effectiveness and results of atrial fibrillation ablation. Cardea SOLO is the first and only wearable cardiac sensor to eliminate the need for expensive and time-consuming third-party service centers and puts the control of patient data, analysis and processing in the hands of physicians and their staffs.

 

The Cardea SOLO sensor records ECG data and patient symptoms. The wearable sensor is small, lightweight (approximately the weight of three quarters), lead-less, water-resistant and single-use disposable. Patients can wear Cardea SOLO comfortably under their clothing for up to seven days and maintain their normal daily activities. “The design and ease-of-use also makes it more likely patients will wear the sensor and capture meaningful data for enhanced evaluation,” according to Harlow.

 

More information is available at http://www.cardiacinsightinc.com.

Suggested Articles

Annual growth of 15% is expected for next decade according to Future Market Insights

New tech relies on time-of-flight sensor tech used in HoloLens combined with CMOS

Edge computing has been around for a while, but the intelligent edge? Ah, come on!